Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.

Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol (2010) 1.30

Current status of biomarkers for prostate cancer. Int J Mol Sci (2013) 1.17

Role of nomograms for prostate cancer in 2007. World J Urol (2007) 0.92

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85

Circulating biomarkers for prostate cancer. World J Urol (2007) 0.82

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer (2009) 0.81

MALDI-target integrated platform for affinity-captured protein digestion. Anal Chim Acta (2013) 0.78

Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody. Anal Chim Acta (2013) 0.76

A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer. Sensors (Basel) (2015) 0.76

Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33

Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61

Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol (1988) 3.20

Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol (1999) 2.48

Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol (2001) 2.15

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem (1995) 1.98

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol (2002) 1.91

The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int (2004) 1.43

In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology (1996) 1.27

Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem (2004) 1.15

Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology (2000) 1.12

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol (2002) 1.12

Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol (2004) 1.06

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology (1999) 1.00

Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate (2005) 0.96

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem (2000) 0.96

Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer (2004) 0.91

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol (2003) 0.88

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate (2003) 0.87

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol (1999) 0.83

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol (2002) 0.82

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. J Urol (2005) 0.82

Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur Urol (2000) 0.80

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol (2003) 0.79

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26

Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93

The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12

NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36

Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22

A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20

Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89

Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42

Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37

Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14

Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10

Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09

Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02

Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72

Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70

Against diagnosis. Ann Intern Med (2008) 3.69

Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol (2008) 3.64

Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ (2013) 3.51

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol (2008) 3.50

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41

Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38

Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36

Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27

Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24

Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23

Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18

Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06

Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04